Literature DB >> 15306104

One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?

J R Oddens1, A P M van der Meijden, R Sylvester.   

Abstract

OBJECTIVE: The optimal treatment for solitary low grade, low stage papillary bladder tumours consists of transurethral resection (TUR) followed by one immediate postoperative instillation with a chemotherapeutic drug. However, when during TUR a bladder perforation or a near-perforation occurs, instillation of a chemotherapeutic drug may lead to leakage outside the bladder, possibly causing severe morbidity. So far, few case reports dealing with complications using mitomycin C have been published, but severe complications of leakage after an early adjuvant instillation with epirubicin have not been reported.
METHODS: We describe 3 patients in whom we observed serious complications of one immediate postoperative instillation of epirubicin.
RESULTS: Two of the patients recovered after conservative therapy, one patient died due to multi organ failure after explorative laparotomy.
CONCLUSION: In order to prevent such complications, an immediate postoperative instillation has to be avoided when there is overt or even suspicion of bladder wall perforation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15306104     DOI: 10.1016/j.eururo.2004.05.003

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  18 in total

1.  Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.

Authors:  Wassim Kassouf; Ashish M Kamat; Alexander Zlotta; Bernard H Bochner; Ronald Moore; Alan So; Jonathan Izawa; Ricardo A Rendon; Louis Lacombe; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

2.  CUA guidelines on the management of non-muscle invasive bladder cancer.

Authors:  Wassim Kassouf; Samer L Traboulsi; Girish S Kulkarni; Rodney H Breau; Alexandre Zlotta; Andrew Fairey; Alan So; Louis Lacombe; Ricardo Rendon; Armen G Aprikian; D Robert Siemens; Jonathan I Izawa; Peter Black
Journal:  Can Urol Assoc J       Date:  2015-10-13       Impact factor: 1.862

3.  Genetic Variations in Glutathione Pathway Genes Predict Cancer Recurrence in Patients Treated with Transurethral Resection and Bacillus Calmette-Guerin Instillation for Non-muscle Invasive Bladder Cancer.

Authors:  Hung-Lung Ke; Jie Lin; Yuanqing Ye; Wen-Jeng Wu; Hui-Hui Lin; Hua Wei; Maosheng Huang; David W Chang; Colin P Dinney; Xifeng Wu
Journal:  Ann Surg Oncol       Date:  2015-04-08       Impact factor: 5.344

4.  Overnight continuous saline irrigation after transurethral resection for non-muscle-invasive bladder cancer is helpful in prevention of early recurrence.

Authors:  Jungmo Do; Sin Woo Lee; Seong Uk Jeh; Jeong Seok Hwa; Jae Seog Hyun; See Min Choi
Journal:  Can Urol Assoc J       Date:  2018-06-08       Impact factor: 1.862

5.  Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors.

Authors:  Zhongbao Zhou; Shikai Zhao; Youyi Lu; Jitao Wu; Yongwei Li; Zhenli Gao; Diandong Yang; Yuanshan Cui
Journal:  World J Urol       Date:  2019-01-05       Impact factor: 4.226

6.  The management of non-invasive bladder tumours with Doxorubicin intravesical instillation after transurethral resection.

Authors:  Musa I Al-Gallab; Louai A Naddaf; Mohamad R Kanan
Journal:  Sultan Qaboos Univ Med J       Date:  2009-03-16

7.  Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial.

Authors:  Cosimo De Nunzio; Antonio Carbone; Simone Albisinni; Giorgio Alpi; Andrea Cantiani; Marcello Liberti; Andrea Tubaro; Francesco Iori
Journal:  World J Urol       Date:  2011-05-19       Impact factor: 4.226

8.  Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer.

Authors:  Hung-Lung Ke; Meng Chen; Yuanqing Ye; Michelle A T Hildebrandt; Wen-Jeng Wu; Hua Wei; Maosheng Huang; David W Chang; Colin P Dinney; Xifeng Wu
Journal:  Carcinogenesis       Date:  2013-01-14       Impact factor: 4.944

9.  Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer.

Authors:  Susumu Kageyama; Koki Maeda; Shigehisa Kubota; Tetsuya Yoshida; Takashi Osafune; Yutaka Arai; Hiroki Soga; Zenkai Nishikawa; Yuji Sakano; Keita Takimoto; Chul Jang Kim; Tokuhiro Chano; Akihiro Kawauchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

10.  Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.

Authors:  S I Tyritzis; Konstantinos G Stravodimos; A Mihalakis; Constantinos A Constantinides
Journal:  Int Urol Nephrol       Date:  2009-03-06       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.